Current Clinical Trial Landscape of OX40 Agonists.
Publication Title
Current oncology reports
Document Type
Article
Publication Date
3-29-2022
Keywords
oregon; portland; eacri; CTLA-4; Cancer immunotherapy; Clinical trials; OX40; PD-1; T cell
Abstract
PURPOSE OF REVIEW: Despite the efficacy of immune checkpoint blockade (ICB) immunotherapy, most cancer patients still develop progressive disease necessitating additional treatment options. One approach is ligation of the OX40 (CD134) costimulatory receptor which promotes T cell activation, effector function, and the generation of long-lived memory cells.
RECENT FINDINGS: Numerous preclinical studies have demonstrated that OX40 agonists alone or in combination with ICB (e.g., anti-PD-1, anti-PD-L1, and anti-CTLA-4) augment anti-tumor immunity. In this review, we discuss the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.
Clinical Institute
Cancer
Specialty/Research Institute
Earle A. Chiles Research Institute
Specialty/Research Institute
Oncology
